WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317552
CAS#: 637-07-0
Description: Clofibrate (Atromid-S) is an aryloxyisobutyric acid derivate with antihyperlipidemic activity. It is marketed as a fibrate. It is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well.
MedKoo Cat#: 317552
Name: Clofibrate
CAS#: 637-07-0
Chemical Formula: C12H15ClO3
Exact Mass: 242.07097
Molecular Weight: 242.7
Elemental Analysis: C, 59.39; H, 6.23; Cl, 14.61; O, 19.78
Synonym: Clofibrate; Ethyl clofibrate; Atromid-S; Clofibrato; Clofibratum;
IUPAC/Chemical Name: ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
InChi Key: KNHUKKLJHYUCFP-UHFFFAOYSA-N
InChi Code: InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3
SMILES Code: CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
Appearance: Colorless to light yellow liquid.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). Light sensitive.
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 242.7 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Chandran K, Goswami S, Sharma-Walia N. Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer. Oncotarget. 2015 Nov 26. doi: 10.18632/oncotarget.6402. [Epub ahead of print] PubMed PMID: 26621841.
2: Takayanagi T, Takashima R, Wako Y, Kawasako K, Tanaka Y, Hori H, Fujii W. Repeated dose liver micronucleus assay using clofibrate in young adult rats. Mutat Res Genet Toxicol Environ Mutagen. 2015 Mar;780-781:117-22. doi: 10.1016/j.mrgentox.2015.01.002. Epub 2015 Jan 6. PubMed PMID: 25892631.
3: Gessner DK, Gröne B, Rosenbaum S, Most E, Hillen S, Becker S, Erhardt G, Reiner G, Eder K. Treatment of lactating sows with clofibrate as a synthetic agonist of PPARα does not influence milk fat content and gains of litters. BMC Vet Res. 2015 Mar 7;11:54. doi: 10.1186/s12917-015-0368-y. PubMed PMID: 25888880; PubMed Central PMCID: PMC4355968.
4: Lin X, Jacobi S, Odle J. Transplacental induction of fatty acid oxidation in term fetal pigs by the peroxisome proliferator-activated receptor alpha agonist clofibrate. J Anim Sci Biotechnol. 2015 Mar 26;6(1):11. doi: 10.1186/s40104-015-0010-7. eCollection 2015. PubMed PMID: 25883783; PubMed Central PMCID: PMC4399351.
5: Bai X, Lin X, Drayton J, Liu Y, Ji C, Odle J. Clofibrate increases long-chain fatty acid oxidation by neonatal pigs. J Nutr. 2014 Nov;144(11):1688-93. doi: 10.3945/jn.114.193169. Epub 2014 Sep 3. PubMed PMID: 25332467.
6: Guo X, Liang XF, Fang L, Yuan X, Zhou Y, He S, Shen D. Effects of lipid-lowering pharmaceutical clofibrate on lipid and lipoprotein metabolism of grass carp (Ctenopharyngodon idellal Val.) fed with the high non-protein energy diets. Fish Physiol Biochem. 2015 Apr;41(2):331-43. doi: 10.1007/s10695-014-9986-8. Epub 2014 Sep 12. PubMed PMID: 25213789.
7: Nafisi S, Heidari R, Ghaffarzadeh M, Ziaee M, Hamzeiy H, Garjani A, Eghbal MA. Cytoprotective effects of silafibrate, a newly-synthesised siliconated derivative of clofibrate, against acetaminophen-induced toxicity in isolated rat hepatocytes. Arh Hig Rada Toksikol. 2014 Jun;65(2):169-78. doi: 10.2478/10004-1254-65-2014-2434. PubMed PMID: 24706421.
8: Fukaya M, Kimata H. Topical clofibrate improves symptoms in patients with atopic dermatitis and reduces serum TARC levels: a randomized, double-blind, placebo-controlled pilot study. J Drugs Dermatol. 2014 Mar;13(3):259-63. PubMed PMID: 24595568.
9: Yousefipour Z, Newaz M. PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats. Acta Pharmacol Sin. 2014 Apr;35(4):476-82. doi: 10.1038/aps.2013.193. Epub 2014 Feb 24. PubMed PMID: 24562305.
10: Eghbalian F, Monsef F, Alam Ghomi N, Monsef A. Effect of Low versus Moderate Dose of Clofibrate on Serum Bilirubin in Healthy Term Neonates with Indirect Hyperbilirubinemia. Iran J Med Sci. 2013 Dec;38(4):349-50. PubMed PMID: 24293792; PubMed Central PMCID: PMC3838990.
